atezolizumab plus bevacizumab
Sponsors
CHA University, Third Affiliated Hospital, Sun Yat-Sen University, Asan Medical Center, Chinese University of Hong Kong
Conditions
Advanced Hepatocellular CarcinomaHCCHepatic Portal Vein Tumor InvasionHepatocellular CancerHepatocellular CarcinomaHepatocellular Carcinoma Non-resectableHepatocellular Carcinoma Stage IVLiver Cancer
Phase 2
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
RecruitingNCT05992220
Start: 2022-10-22End: 2026-03-31Target: 138Updated: 2025-02-21
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
RecruitingNCT06823375
Start: 2025-07-10End: 2028-07-31Target: 40Updated: 2026-03-04
Unknown Phase
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CompletedNCT04862949
Start: 2021-05-01End: 2023-03-09Updated: 2025-12-12
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
RecruitingNCT05173298
Start: 2021-08-02End: 2024-12-31Target: 100Updated: 2024-02-07
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy
CompletedNCT05197504
Start: 2021-12-20End: 2023-12-31Updated: 2025-09-05
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
RecruitingNCT05984511
Start: 2023-08-30End: 2029-08-01Target: 234Updated: 2025-02-11